Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06172621
Other study ID # B4258-R
Secondary ID 1I01RX004258
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2024
Est. completion date February 29, 2028

Study information

Verified date April 2024
Source VA Office of Research and Development
Contact Francisco E Castano, MPH
Phone (718) 584-9000
Email francisco.castano@va.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). The investigators have shown that synchronized stimulation over the brain and cervical spinal cord can temporarily strengthen weakened nerve circuits between the brain and hand muscles in people with ALS. The current proposal will take the next step of individualizing this intervention, then applying it repetitively in an attempt to achieve direct clinical benefit on hand strength and function. Following an initial 2-3 month period of optimizing the intervention for each individual, the investigators will compare the effects of two-week programs of paired brain-spinal stimulation with or without hand exercises.


Description:

Amyotrophic lateral sclerosis (ALS) is more prevalent in Veterans than civilians, leading to ALS being considered a Service-Connected condition by the VA. ALS features incomplete degeneration of upper and lower motor neuron pathways within the spinal cord, a circumstance resembling that of spinal cord injury (SCI). Transcutaneous spinal cord stimulation (TSCS) has demonstrated remarkable potential to activate damaged circuits after SCI to improve motor and autonomic function. Partly funded by a prior VA award (RX002527), the investigators have preliminary data demonstrating that pairing subthreshold cervical TSCS pulses with suprathreshold transcranial magnetic stimulation (TMS) pulses can enhance hand muscle motor evoked potentials when the cortical pulse reaches the cervical spinal cord 0-5 milliseconds prior to the spinal pulse. This evidence for immediate facilitation of the response to one pair of pulses suggests that if given repetitively, this approach could mediate spinal cord associative plasticity (SCAP) outlasting the period of paired stimulation. The investigators propose that increasing neural plasticity in this manner could be applied as a method to strengthen volitional (cortical) motor output and/or to 'prime' weakened circuits for improved responses to task-oriented exercise. Both exercise and neuromodulation are understudied in ALS. Though not likely to cure the underlying disease mechanism, these approaches have the potential to mediate symptomatic benefit. The investigators strive to find better ways to conduct disease-oriented research that may provide direct clinical benefit to research participants with ALS and simultaneously increase scientific understanding. Additionally, most ALS clinical study entry criteria heavily favor those at earlier stages of disease. Strict entry criteria are understandable from the scientific perspective. However, we have repeatedly observed the frustration and rejection felt by individuals with ALS who cannot enter clinical trials. This proposed study does not restrict entry by time since symptom onset. The investigators thereby hope to produce more generalizable knowledge by performing a phased study: 1. Optimization: SCAP synaptic pairing interval and repetitive frequency pattern will be individually optimized to enhance hand muscle excitability and dexterity. The investigators hypothesize that pairs of stimuli with TMS arriving at the cervical spinal cord up to 2 ms prior to TSCS, delivered in an 'intermittent theta burst' pattern, will produce the strongest facilitation of hand neural circuits. 2. Consolidation: Two-week programs of SCAP alone versus SCAP plus task-oriented hand exercise will be compared. The investigators hypothesize that the combined intervention will result in greater and longer lasting physiological and clinical benefits than SCAP by itself. There are currently no clinical studies in the world involving magnetic brain paired with phasic electrical spinal stimulation for ALS. Therefore, safety needs to be meticulously tracked. Aside from detailed clinical safety measures, the investigators will analyze serum biomarkers drawn at baseline and various stages of the study to better understand whether baseline levels of neurodegenerative, excitotoxic, inflammatory, and neurotropic biomarkers associate with either beneficial or detrimental responses to SCAP and exercise interventions.


Recruitment information / eligibility

Status Recruiting
Enrollment 32
Est. completion date February 29, 2028
Est. primary completion date November 30, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Diagnosis of ALS by Gold Coast Criteria (Shefner et al. 2020) or "definite" or "probable" ALS by revised El Escorial Criteria (Brooks et al. 2000) - Incomplete weakness: Score of 1, 2, 3, or 4 (out of 5) on manual muscle testing of finger extension, finger flexion, or finger abduction in left or right hand - TSCS-evoked potential amplitude of at least 25 V in left or right abductor pollicis brevis (APB) or first dorsal interosseous (FDI) muscles with a resting motor threshold of 55 mA or lower - TMS-evoked potential amplitude of at least 25 V in left or right abductor pollicis brevis (APB) or first dorsal interosseous (FDI) muscles with a resting motor threshold of 65% MSO or lower Exclusion Criteria: - History of seizures - Ventilator dependence or patent tracheostomy site - Use of medications that significantly lower seizure threshold, such as amphetamines and dalfampridine - History of severe head trauma (evidence of brain contusion or hemorrhage or depressed skull fracture on prior imaging) - History of implanted brain/spine/nerve stimulators, aneurysm clips, ferromagnetic metallic implants in the head (except for inside mouth); cochlear implants; cardiac pacemaker/defibrillator; intracardiac lines; currently increased intracranial pressure; or other contraindications to brain or spine stimulation - Significant coronary artery or cardiac conduction disease; heart failure with an ejection fraction of less than 30% or with a New York Heart Association Functional Classification of Class III or IV - History of significant tinnitus - History of bipolar disorder - History of suicide attempt - Active psychosis - Ongoing illicit drug or alcohol abuse in the past 6 months - Heavy alcohol consumption (greater than equivalent of 5 ounces of liquor) within previous 48 hours - Open skin lesions over the neck, shoulders, or arm stimulation or recording sites - Pregnancy

Study Design


Intervention

Procedure:
Spinal Cord Associative Plasticity (SCAP)
Paired non-invasive brain and spinal cord stimulation.
Upper extremity task-oriented exercise
Participants will perform a range of exercises composed of tasks resembling daily home/community activities such as stacking and sorting small objects, manipulating writing utensils, keys, buttons, etc.

Locations

Country Name City State
United States James J. Peters VA Medical Center, Bronx, NY Bronx New York

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Amplitude of intrinsic hand muscle response to single-pulse transcranial magnetic stimulation (TMS) The primary neurophysiological outcome will be corticospinal excitability measured at the first dorsal interosseous (FDI) muscle. If no suitable FDI muscle, will substitute with abductor pollicis brevis (APB) muscle. Through study completion, up to 6 months
Primary Hand dexterity on the nine-hole peg test Time to complete placement of nine pegs into their respective holes using the target hand. Through study completion, up to 6 months
Secondary Volitional strength assessed by isometric dynamometry (key-pinch configuration) Maximal isometric pinch strength will be measured using a pinch dynamometer. Maximum volitional force will be applied for 3-5 seconds, with at least 30 seconds between trials. The highest achieved value will be used for analysis. Through study completion, up to 6 months
Secondary Volitional strength assessed by isometric dynamometry (tip-to-tip configuration) Maximal isometric pinch strength will be measured using a pinch dynamometer. Maximum volitional force will be applied for 3-5 seconds, with at least 30 seconds between trials. The highest achieved value will be used for analysis. Through study completion, up to 6 months
Secondary Volitional strength assessed by isometric dynamometry (grip configuration) Maximal isometric pinch strength will be measured using a hand dynamometer. Maximum volitional force will be applied for 3-5 seconds, with at least 30 seconds between trials. The highest achieved value will be used for analysis. Through study completion, up to 6 months
See also
  Status Clinical Trial Phase
Terminated NCT04428775 - A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease Phase 2
Recruiting NCT04998305 - TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps Phase 1/Phase 2
Recruiting NCT05951556 - Telehealth Implementation of Brain-Computer Interface N/A
Terminated NCT04579666 - MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT04082832 - CuATSM Compared With Placebo for Treatment of ALS/MND Phase 2/Phase 3
Completed NCT01925196 - Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Completed NCT02496767 - Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Phase 3
Recruiting NCT04816227 - Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
Active, not recruiting NCT04494256 - A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation Phase 1/Phase 2
Completed NCT03706391 - Study of ALS Reversals 4: LifeTime Exposures
Recruiting NCT04882904 - Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part. N/A
Completed NCT04557410 - Open Label Study: Treatment of ALS Fatigue With PolyMVA Phase 1
Active, not recruiting NCT04948645 - A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis Phase 1
Not yet recruiting NCT04089696 - Validation of the "ExSpiron©" in Patients With ALS N/A
Not yet recruiting NCT05860244 - Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients Phase 2
Recruiting NCT02917681 - Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis Phase 1/Phase 2
Active, not recruiting NCT03067857 - Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease Phase 1/Phase 2
Recruiting NCT02874209 - Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis N/A
Active, not recruiting NCT02567136 - Imaging Biomarkers in ALS
Completed NCT02059759 - Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 Phase 2